REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.

The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants had baseline LDL-C levels of 41-100mg/dL and were randomized to receive either icosapent ethyl or placebo. The primary composite endpoint encompassed cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina.

Findings showed that among patients with elevated triglycerides and high CV risk, icosapent ethyl reduced the rate of cardiovascular endpoints regardless of baseline LDL-C.

Interview Questions:
Can you explain the primary objective of the REDUCE-IT trial and how this post hoc analysis contributes to understanding icosapent ethyl's efficacy?
What were the key findings of the secondary analysis?
How might these findings impact current clinical practice for patients with elevated triglycerides and high cardiovascular risk?
What questions would you want to explore in future research based on these findings?

Editors: Jordan Rance, Yazmin Sadik
Video Specialist: David Ben-Harosh

Recorded remotely from New York, 2025.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Category
Cardiology
Be the first to comment

Up Next